CJC-1295 with DAC is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) developed to evaluate extended pharmacokinetics in endocrine models. By incorporating a Drug Affinity Complex (DAC), the peptide bioconjugates to circulating serum albumin, enabling researchers to investigate sustained growth hormone release over prolonged timeframes. PX1 Research supplies high-purity, US-manufactured CJC-1295 with DAC accompanied by lot-specific analytical documentation for in vitro and preclinical applications.
CJC-1295 with DAC is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) developed to evaluate extended pharmacokinetics in endocrine models. By incorporating a Drug Affinity Complex (DAC), the peptide bioconjugates to circulating serum albumin, enabling researchers to investigate sustained growth hormone release over prolonged timeframes. PX1 Research supplies high-purity, US-manufactured CJC-1295 with DAC accompanied by lot-specific analytical documentation for in vitro and preclinical applications.
CJC-1295 with DAC is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH) modified with a reactive Lys(maleimidopropionic acid) group at its C-terminus. This Drug Affinity Complex (DAC) permits covalent bioconjugation to endogenous serum albumin post-administration in preclinical models. Consequently, the compound maintains an extended biological half-life, providing sustained stimulation of somatotropes to evaluate chronic baseline elevations in growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
Within cell culture systems and animal models, researchers evaluate CJC-1295 with DAC to determine how persistent GHRH receptor signaling influences systemic protein synthesis, nitrogen retention, and cellular turnover. Unlike native GHRH, which experiences rapid enzymatic degradation within minutes, the presence of the DAC moiety shields the peptide chain against cleavage by circulating dipeptidyl peptidase IV (DPP-IV). This stability makes it a core subject within the broader study of growth hormone-releasing hormone (GHRH) analogs.
The primary structure of CJC-1295 is derived from the first 29 amino acids of native GHRH, modified at four specific amino acid residues (Tyr1, Ala2, Asp3, and Gln8 substituted with D-Ala2, Gln8, Ala15, and Leu27) to improve enzymic resistance. The defining addition is the maleimido-propionic acid (MPA) linker attached via a lysine residue at position 30. This electrophilic linker preferentially reacts with the free thiol group on Cys34 of circulating albumin, forming a stable thioether bond.
This covalent binding mechanism transforms human or rodent serum albumin into a protective carrier matrix. Because serum albumin has a extended degradation cycle in circulation, the conjugated peptide evades renal clearance and enzymatic breakdown. Pharmacokinetic evaluations in rodent and non-human primate models reveal an elimination half-life extending from 6 to 8 days, contrasting dramatically with non-conjugated peptides that degrade within 30 minutes of reconstitution and administration.
At the cellular level, CJC-1295 with DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor primarily localized on somatotrope cells in the anterior pituitary gland. Upon binding, the receptor couples with the Gs alpha subunit, activating adenylate cyclase. This enzyme catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), triggering downstream activation of protein kinase A (PKA).
The resulting signaling cascade opens voltage-gated calcium channels, promoting an influx of intracellular calcium that stimulates the exocytosis of stored growth hormone granules into circulation. Concurrently, phosphorylated transcription factors (such as CREB) increase the gene expression of pituitary-specific positive transcription factor 1 (Pit-1), promoting de novo GH synthesis. Circulating GH subsequently interacts with hepatic GH receptors to upregulate the expression and secretion of insulin-like growth factor 1 (IGF-1), a primary mediator of cell proliferation, tissue repair, and extracellular matrix remodeling in experimental paradigms.
In animal models examining musculoskeletal regeneration, preclinical studies suggest that sustained GHRH signaling via CJC-1295 with DAC accelerates cellular repair mechanisms following induced tissue injury. The prolonged elevation of serum IGF-1 promotes satellite cell activation in skeletal muscle tissue, leading to enhanced protein synthesis rates and faster restoration of contractile force in rodent models of muscle damage. Additionally, researchers utilizing fibroblast cultures have documented increased collagen type I and III transcription following exposure to elevated IGF-1 concentrations generated downstream of GHRH activation.
Metabolic research utilizing animal models demonstrates that continuous GHRHR activation by CJC-1295 with DAC significantly alters nutrient partitioning. Rodent models exhibit increased lipid oxidation alongside decreased adipocyte mass without altering net caloric intake. This lipolytic activity is attributed to GH-induced inhibition of lipoprotein lipase (LPL) in adipose tissue and the concurrent activation of hormone-sensitive lipase (HSL). Furthermore, marked improvements in systemic nitrogen balance have been recorded, reflecting an increase in lean tissue preservation during periods of metabolic stress or catabolic state modeling.
When evaluating compounds within the class of growth hormone secretagogues, investigators select specific peptides based on desired kinetic profiles. The primary distinction between CJC-1295 with DAC and CJC-1295 No DAC lies in their active half-life and secretion patterns. While the DAC variant provides continuous, non-pulsatile elevation of basal GH levels over several days, CJC-1295 No DAC (often combined with a GHRP) exhibits a short half-life of approximately 30 minutes, producing rapid, acute physiological pulses of GH release.
Researchers also contrast CJC-1295 with DAC against ghrelin mimetics and short-acting peptides such as Ipamorelin and Tesamorelin. Ipamorelin acts via the growth hormone secretagogue receptor (GHS-R1a) to induce short, selective GH spikes without influencing cortisol or prolactin. Tesamorelin, another GHRH analog, features a trans-3-hexenoic acid modification tailored for acute pituitary stimulation rather than systemic albumin binding. Understanding these comparative mechanisms enables researchers cataloging agents from the PX1 Research library to design targeted protocols measuring either continuous endocrine saturation or episodic pulsatile dynamics.
CJC-1295 with DAC is supplied as a lyophilized white powder under vacuum seal to ensure chemical stability during transport and storage. To maintain structural integrity for in vitro assays, researchers must follow strict aseptic handling protocols. Prior to reconstitution, unopened vials should be stored in a freezer at -20°C, isolated from moisture and direct light exposure. Under these conditions, the lyophilized peptide remains stable for extended storage periods.
Reconstitution should be performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the biological model. The diluent should be introduced gently along the internal glass wall of the vial, allowing the solvent to dissolve the cake without vigorous agitation to avoid shearing the peptide chain. Once reconstituted, the liquid solution must be stored at 2°C to 8°C and used within 30 days. For long-term analytical testing, reconstituting into single-use aliquots and freezing at -80°C prevents degradation associated with repeated freeze-thaw cycles.
Assessing the purity and sequence fidelity of CJC-1295 with DAC is critical for reproducible scientific research. Lower-grade synthetic peptides often contain truncation sequences, deletion peptides, or residual counter-ions that alter experimental results or cause cytotoxic effects in cell culture. PX1 Research enforces rigorous quality control protocols for every manufactured lot, utilizing state-of-the-art analytical instrumentation.
Every production lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity, ensuring target compound concentration exceeds 99%. Mass Spectrometry (MS) analysis is simultaneously performed to verify the exact molecular weight and confirm the presence of the active maleimide bioconjugate linker. Furthermore, chromogenic Limulus Amebocyte Lysate (LAL) testing is conducted to verify endotoxin levels remain strictly below < 0.01 EU/mg, protecting cell assays and animal models from inflammatory interference.
When purchasing compounds across the full catalog of research peptides, research institutions demand full supply-chain transparency and lot-to-lot consistency. PX1 Research operates USA-based, GMP-compliant facilities adhering to ISO 17025 laboratory standards. Every peptide shipment includes an accessible Certificate of Analysis (COA) detailing the verified HPLC chromatogram, mass spectra, and endotoxin assessment for that specific lot number.
To accommodate both pilot assays and continuous academic studies, PX1 Research offers flexible ordering options, including direct fulfillment for research institutions and established wholesale lab accounts. Orders placed Monday through Friday ship same-day from distribution hubs in California and Arizona, ensuring minimal transit times and preserving peptide integrity throughout delivery.
What is the key difference between CJC-1295 with DAC and CJC-1295 No DAC?
The key difference is the inclusion of the Drug Affinity Complex (DAC), a maleimido-propionic acid linker. The DAC moiety allows the peptide to covalently bind to serum albumin, extending its biological half-life from approximately 30 minutes (No DAC) to 6–8 days (with DAC) in preclinical models.
What is the primary mechanism of action of CJC-1295 with DAC?
CJC-1295 with DAC functions as a GHRH receptor agonist on pituitary somatotropes. It stimulates the cAMP/PKA intracellular pathway, promoting endogenous growth hormone synthesis and secretion, which subsequently increases systemic IGF-1 production in liver tissue.
How should CJC-1295 with DAC be stored prior to reconstitution?
Lyophilized CJC-1295 with DAC should be stored in a dry, dark environment at -20°C for optimal long-term stability. Avoid exposure to heat, light, and ambient moisture until reconstitution.
What solvent is recommended for reconstituting CJC-1295 with DAC for laboratory use?
Reconstitution is typically performed using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride injection solution. Solvent choice depends on the specific in vitro or preclinical experimental model.
How does PX1 Research verify the quality and purity of CJC-1295 with DAC?
Every lot undergoes independent ISO 17025 analytical testing, including RP-HPLC for purity confirmation (>99%), Mass Spectrometry for structural sequence validation, and LAL assays to ensure endotoxin levels remain below 0.01 EU/mg.
Can CJC-1295 with DAC be frozen after reconstitution?
Yes, reconstituted solution can be split into single-use laboratory aliquots and stored at -80°C to prevent peptide degradation. Repeated freeze-thaw cycles must be strictly avoided to prevent physical denaturation of the peptide chain.
Is CJC-1295 with DAC approved for human clinical use or therapy?
No. CJC-1295 with DAC is strictly a research chemical designated for laboratory, in vitro, and preclinical research applications only. It is not intended for human consumption, clinical diagnostic procedures, or therapeutic use.
What research areas commonly utilize CJC-1295 with DAC in preclinical models?
It is predominantly studied in models of endocrine signaling, continuous growth hormone receptor kinetics, tissue repair, collagen deposition, skeletal muscle protein synthesis, and metabolic lipid oxidation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.